These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18828017)

  • 1. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells.
    Liu Y; Yu Y; Yang S; Zeng B; Zhang Z; Jiao G; Zhang Y; Cai L; Yang R
    Cancer Immunol Immunother; 2009 May; 58(5):687-97. PubMed ID: 18828017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.
    Liu Y; Zeng B; Zhang Z; Zhang Y; Yang R
    Clin Immunol; 2008 Dec; 129(3):471-81. PubMed ID: 18790673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
    Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
    Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
    Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
    Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.
    Kapanadze T; Medina-Echeverz J; Gamrekelashvili J; Weiss JM; Wiltrout RH; Kapoor V; Hawk N; Terabe M; Berzofsky JA; Manns MP; Wang E; Marincola FM; Korangy F; Greten TF
    Eur J Immunol; 2015 Apr; 45(4):1148-58. PubMed ID: 25616156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
    Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
    Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
    J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
    Krempski J; Karyampudi L; Behrens MD; Erskine CL; Hartmann L; Dong H; Goode EL; Kalli KR; Knutson KL
    J Immunol; 2011 Jun; 186(12):6905-13. PubMed ID: 21551365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.
    Phares TW; Ramakrishna C; Parra GI; Epstein A; Chen L; Atkinson R; Stohlman SA; Bergmann CC
    J Immunol; 2009 May; 182(9):5430-8. PubMed ID: 19380790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
    Goldberg MV; Maris CH; Hipkiss EL; Flies AS; Zhen L; Tuder RM; Grosso JF; Harris TJ; Getnet D; Whartenby KA; Brockstedt DG; Dubensky TW; Chen L; Pardoll DM; Drake CG
    Blood; 2007 Jul; 110(1):186-92. PubMed ID: 17392506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
    Hori J; Wang M; Miyashita M; Tanemoto K; Takahashi H; Takemori T; Okumura K; Yagita H; Azuma M
    J Immunol; 2006 Nov; 177(9):5928-35. PubMed ID: 17056517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.
    Wei S; Shreiner AB; Takeshita N; Chen L; Zou W; Chang AE
    Cancer Res; 2008 Jul; 68(13):5432-8. PubMed ID: 18593946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
    LaBelle JL; Hanke CA; Blazar BR; Truitt RL
    Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
    Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
    Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Blank C; Gajewski TF; Mackensen A
    Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.